262 related articles for article (PubMed ID: 37404815)
21. Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.
Ngare I; Tan TS; Toyoda M; Kuwata T; Takahama S; Nakashima E; Yamasaki N; Motozono C; Fujii T; Minami R; Barabona G; Ueno T
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675897
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
Cai S; Liao G; Yu T; Gao Q; Zou L; Zhang H; Xu X; Chen J; Lu A; Wu Y; Li B; Peng J
J Med Virol; 2022 Sep; 94(9):4224-4233. PubMed ID: 35585023
[TBL] [Abstract][Full Text] [Related]
23. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study.
Wang H; Gan M; Wu B; Zeng R; Wang Z; Xu J; Li J; Zhang Y; Cao J; Chen L; Di D; Peng S; Lei J; Zhao Y; Song X; Yuan T; Zhou T; Liu Q; Yi J; Wang X; Cai H; Lei Y; Wen Y; Li W; Chen Q; Wang Y; Long P; Yuan Y; Wang C; Pan A; Wang Q; Gong R; Fan X; Wu T; Liu L
J Med Virol; 2023 Jan; 95(1):e28380. PubMed ID: 36478357
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
[TBL] [Abstract][Full Text] [Related]
25. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
26. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
27. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Vaccine-Induced T-Cell Response after Three Doses in People Living with HIV on Antiretroviral Therapy Compared to Seronegative Controls (CTN 328 COVAXHIV Study).
Alexandrova Y; Yero A; Mboumba Bouassa RS; Comeau E; Samarani S; Brumme ZL; Hull M; Crawley AM; Langlois MA; Angel JB; Cooper CL; Needham J; Lee T; Singer J; Anis AH; Costiniuk CT; Jenabian MA
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851789
[TBL] [Abstract][Full Text] [Related]
29. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study.
Kuloğlu ZE; El R; Guney-Esken G; Tok Y; Talay ZG; Barlas T; Kuskucu MA; Albayrak Ö; Doğan Ö; Yavuz SŞ; Midilli K; Ergönül Ö; Can F
Allergy; 2022 Aug; 77(8):2459-2467. PubMed ID: 35437772
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
31. Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
Yi X; Wang Y; Li Q; Li X; Zhang P; Fu X; Gu S; Zhang D; Liu X; Lou H; Wu Y; Tang L; Hou J; Li Y
J Med Virol; 2023 Mar; 95(3):e28642. PubMed ID: 36890630
[TBL] [Abstract][Full Text] [Related]
32. Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV.
El Moussaoui M; Desmecht S; Lambert N; Maes N; Braghini J; Marechal N; Quintana C; Briquet K; Gofflot S; Toussaint F; Hayette MP; Vermeersch P; Lutteri L; Grégoire C; Beguin Y; Rahmouni S; Moutschen M; Desmecht D; Darcis G
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515123
[TBL] [Abstract][Full Text] [Related]
33. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.
Cheng MQ; Li R; Weng ZY; Song G
Front Med (Lausanne); 2023; 10():1275843. PubMed ID: 37877024
[TBL] [Abstract][Full Text] [Related]
35. Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine.
Huang R; Ying L; Wang J; Xia J; Zhang Y; Mao H; Zhang R; Zang R; Le Z; Shu Q; Xu J
Front Immunol; 2023; 14():1139620. PubMed ID: 37114058
[TBL] [Abstract][Full Text] [Related]
36. Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
Cheng ZJ; Huang H; Liu Q; Zhong R; Liang Z; Xue M; Liu M; Li S; Wang H; Zheng P; Zheng C; Sun B
J Med Virol; 2022 Nov; 94(11):5206-5216. PubMed ID: 35801663
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
38. Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China.
Yi Y; Han X; Cui X; Wang P; Wang X; Liu H; Wang Y; Zhu N; Li Y; Lin Y; Li X
Vaccines (Basel); 2023 May; 11(6):. PubMed ID: 37376408
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
40. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
Wang Y; Li J; Zhang W; Liu S; Miao L; Li Z; Fu A; Bao J; Huang L; Zheng L; Li E; Zhang Y; Yu J
Front Immunol; 2023; 14():1152695. PubMed ID: 36936952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
